Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells

Triple negative breast cancer holds a dismal clinical outcome and as such, patients routinely undergo aggressive, highly toxic treatment regimens. Clinical trials for TNBC employing immune checkpoint blockade in combination with chemotherapy show modest prognostic benefit, but the percentage of pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Vito, Alyssa, Salem, Omar, El-Sayes, Nader, MacFawn, Ian P., Portillo, Ana L., Milne, Katy, Harrington, Danielle, Ashkar, Ali A., Wan, Yonghong, Workenhe, Samuel T., Nelson, Brad H., Bruno, Tullia C., Mossman, Karen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275624/
https://www.ncbi.nlm.nih.gov/pubmed/34253827
http://dx.doi.org/10.1038/s42003-021-02375-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275624/
https://www.ncbi.nlm.nih.gov/pubmed/34253827
http://dx.doi.org/10.1038/s42003-021-02375-9

Ejemplares similares